NEW ANTIPLATELET DRUGS (PART 1)
Рациональная фармакотерапия в кардиологии, 2016 Antiplatelet agents are a necessary component of modern atherosclerosis therapy. The difficulties of antiplatelet treatment lie in the balance between the necessary therapeutic effect of the drug and the risk of excessive action leading to the bleeding ...
A. B. Sumarokov
doaj +3 more sources
Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. [PDF]
, 2020 Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ...
Bassand, J-P +17 more
core +2 more sources
Antiplatelet drugs and liver fibrosis
Platelets, 2022 Liver fibrosis results from an imbalance between extracellular matrix formation and degradation. The background of liver fibrosis is chronic inflammation and subsequent microcirculation disturbance including microthrombosis.
Pamela Czajka +7 more
doaj +1 more source
Research progress of antithrombotic drugs [PDF]
Jichu yixue yu linchuang, 2023 Thrombosis is the main direct cause of acute manifestations of atherosclerotic cardiovascular disease (myocardial infarction, stroke). Globally, the incidence of thromboembolic diseases has increased in recent years, accompanied by an increase in patient
ZHANG Jie, MA Xuzhou, LI Huihui, WANG Miao
doaj +1 more source
Correlation between prescribing quality and pharmaceutical costs in English primary care: national cross-sectional analysis [PDF]
, 2011 Background Both pharmaceutical costs and quality-indicator performance vary substantially between general practices, but little is known about the relationship between prescribing costs and quality Aim To measure the association between prescribing ...
Allsup +8 more
core +1 more source
Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study. [PDF]
, 2014 ObjectiveThere is insufficient evidence on which to base a recommendation for optimal antiplatelet therapy following a stroke while on aspirin. The objective was to compare clopidogrel initiation vs aspirin reinitiation for vascular risk reduction among ...
Chang, Ku-Chou +10 more
core +1 more source
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial [PDF]
, 2019 Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage.
Al-Shahi Salman, Rustam +16 more
core +1 more source
Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. [PDF]
, 2020 Background Reducing major bleeding events is a challenge when managing anticoagulation in patients with atrial fibrillation. This study evaluated the impact of modifiable and nonmodifiable bleeding risk factors in patients with atrial fibrillation ...
Amarenco, P +8 more
core +2 more sources
Adherence to secondary stroke prevention strategies - Results from the German stroke data bank [PDF]
, 2003 Only very limited data are available concerning patient adherence to antithrombotic medication intended to prevent a recurrent stroke. Reduced adherence and compliance could significantly influence the effects of any stroke prevention strategies.
Busse, O. +4 more
core +1 more source
Pharmacogenetics of Antiplatelet Drugs
The Scientific World Journal, 2002 Pharmacogenetics refers to the genetic factors that influence the response to a drug, often involving genetic variations in drug metabolizing enzymes. The pharmacogenetics of antiplatelet agents is in its infancy and largely reflects variations in drug ...
Ronan Curtin, Desmond J. Fitzgerald
doaj +1 more source